HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Menzel, C. Articles by Grünwald, F. Search for Related Content PubMed PubMed Citation Articles by Menzel, C. Articles by Grünwald, F.

rhTSH Stimulation Before Radioiodine Therapy in Thyroid Cancer Reduces the Effective Half-Life of ¹³¹I

Department of Nuclear Medicine, Hospital of the Johann W. Goethe University, Frankfurt, Germany

Recombinant human thyroid-stimulating hormone (rhTSH) is effectively used for exogenous thyroid-stimulating hormone (TSH) stimulation before diagnostic ¹³¹I scintigraphy. It is not yet widely used for preparation of patients receiving a therapeutic amount of radioiodine. Methods: The results of 64 consecutive therapeutic applications of rhTSH with regard to clinical tolerance and side effects were evaluated in comparison with 163 radioiodine therapies (RITs) done on patients with hypothyroidism after thyroxine withdrawal during the same period. All therapies—applying 1.1–10 GBq of ¹³¹I—used a standardized protocol of patient preparation and activity application. RITs were followed by daily whole-body uptake measurements for 2–6 d, and a biexponential curve fit was used to obtain a short initial and afterward a long effective half-life of ¹³¹I. Patients after rhTSH were evaluated as a whole group (group A, n = 64) and as a subset of that group with normal thyroglobulin (hTG) levels (group D, n = 18). Patients after endogenous TSH stimulation were evaluated as a whole group (group B, n = 163), as a subset of that group excluding all ablative RITs (group C, n = 113), and as a subset of that subset with normal hTG levels (group E, n = 87). Results: rhTSH-stimulated patients showed significantly higher TSH values than did endogenously stimulated patients (P < 0.001). Furthermore, the effective half-life of ¹³¹I was significantly prolonged after endogenous stimulation (e.g., 0.43 d for group A vs. 0. 54 d for group B, P < 0.001). All rhTSH applications were tolerated well and without serious side effects. The only side effects were 2 cases of nausea and headache. Conclusion: The use of rhTSH for stimulation of TSH before RIT is safe but also significantly reduces the effective half-life of ¹³¹I. This is mainly due to a reduced renal iodine clearance in the hypothyroid state, but the bioavailability of radioiodine may be slightly overestimated because of larger amounts of intestinal ¹³¹I after endogenous TSH stimulation.

Key Words: thyroid cancer • rhTSH • radioiodine • effective half-life

This article has been cited by other articles:

				R. K. Grewal, S. M. Larson, C. E. Pentlow, K. S. Pentlow, M. Gonen, R. Qualey, L. Natbony, and R. M. Tuttle Salivary Gland Side Effects Commonly Develop Several Weeks After Initial Radioactive Iodine Ablation J. Nucl. Med., October 1, 2009; 50(10): 1605 - 1610. [Abstract] [Full Text] [PDF]

				P. W. Rosario, M. A. R. Borges, and S. Purisch Preparation with Recombinant Human Thyroid-Stimulating Hormone for Thyroid Remnant Ablation with 131I Is Associated with Lowered Radiotoxicity J. Nucl. Med., November 1, 2008; 49(11): 1776 - 1782. [Abstract] [Full Text] [PDF]

				H. Remy, I. Borget, S. Leboulleux, N. Guilabert, F. Lavielle, J. Garsi, C. Bournaud, S. Gupta, M. Schlumberger, and M. Ricard 131I Effective Half-Life and Dosimetry in Thyroid Cancer Patients J. Nucl. Med., September 1, 2008; 49(9): 1445 - 1450. [Abstract] [Full Text] [PDF]

				C. C. Travis and M. G. Stabin 131I Ablation Treatment in Young Females After the Chernobyl Accident J. Nucl. Med., October 1, 2006; 47(10): 1723 - 1727. [Abstract] [Full Text] [PDF]

				P Mernagh, S Campbell, M Dietlein, M Luster, E Mazzaferri, and A R Weston Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective Eur. J. Endocrinol., September 1, 2006; 155(3): 405 - 414. [Abstract] [Full Text] [PDF]

				M. Luster, F. Lippi, B. Jarzab, P. Perros, M. Lassmann, C. Reiners, and F. Pacini rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review Endocr. Relat. Cancer, March 1, 2005; 12(1): 49 - 64. [Abstract] [Full Text] [PDF]

				K. Nakada, T. Ishibashi, T. Takei, K. Hirata, K. Shinohara, S. Katoh, S. Zhao, N. Tamaki, Y. Noguchi, and S. Noguchi Does Lemon Candy Decrease Salivary Gland Damage After Radioiodine Therapy for Thyroid Cancer? J. Nucl. Med., February 1, 2005; 46(2): 261 - 266. [Abstract] [Full Text] [PDF]

				B. de Keizer, A. Hoekstra, M. W. Konijnenberg, F. de Vos, B. Lambert, P. P. van Rijk, C. J.M. Lips, and J. M.H. de Klerk Bone Marrow Dosimetry and Safety of High 131I Activities Given After Recombinant Human Thyroid-Stimulating Hormone to Treat Metastatic Differentiated Thyroid Cancer J. Nucl. Med., September 1, 2004; 45(9): 1549 - 1554. [Abstract] [Full Text] [PDF]

				R. J. Robbins and K. S. Pentlow Coming of Age: Recombinant Human Thyroid-Stimulating Hormone as a Preparation for 131I Therapy in Thyroid Cancer J. Nucl. Med., July 1, 2003; 44(7): 1069 - 1071. [Full Text] [PDF]